In conclusion, our study is the first comprehensive analysis to demonstrate that NAPSB could shape an immuno-hot and inflamed TME in HCC; NAPSB could be considered a predictor of disease-free and progression-free survival outcomes in patients with HCC; NAPSB can also predict the clinical response to ICB and chemotherapy. This evidence concerns the gene NAPSB and hepatocellular carcinoma.